Enveric Average Payables vs Price To Sales Ratio Analysis

ENVB Stock

USD 0.33 0.01 3.13%

Enveric Biosciences financial indicator trend analysis is much more than just examining Enveric Biosciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Enveric Biosciences is a good investment. Please check the relationship between Enveric Biosciences Average Payables and its Price To Sales Ratio accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.

Average Payables vs Price To Sales Ratio

Average Payables vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Enveric Biosciences Average Payables account and Price To Sales Ratio. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Enveric Biosciences' Average Payables and Price To Sales Ratio is -0.25. Overlapping area represents the amount of variation of Average Payables that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Enveric Biosciences, assuming nothing else is changed. The correlation between historical values of Enveric Biosciences' Average Payables and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Average Payables of Enveric Biosciences are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Average Payables i.e., Enveric Biosciences' Average Payables and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

-0.25

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Enveric Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Enveric Biosciences sales, a figure that is much harder to manipulate than other Enveric Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from Enveric Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Enveric Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.As of December 1, 2024, Selling General Administrative is expected to decline to about 6.3 M. The current year's Tax Provision is expected to grow to about (1.4 M)

	2021	2022	2023	2024 (projected)
Total Operating Expenses	25.9M	20.0M	16.4M	17.3M
Cost Of Revenue	681.6K	435.2K	408.0K	387.6K

Total Operating Expenses Cost Of Revenue

Enveric Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Short Term Debt	Common Stock	Current Deferred Revenue	Common Stock Total Equity
Total Assets		0.81	0.89	0.85	-0.03	0.04	0.32	0.72	0.33	0.88	0.0	0.33	0.47	-0.18	0.56	-0.21	0.35	-0.12	0.92	0.79	0.81	0.54	0.63	0.35	-0.65	0.09
Other Current Liab	0.81		0.94	0.58	-0.13	0.22	0.31	0.78	0.11	0.79	0.18	0.11	0.49	-0.14	0.2	-0.14	0.28	-0.16	0.83	0.53	0.61	0.57	0.56	0.14	-0.4	0.12
Total Current Liabilities	0.89	0.94		0.6	-0.23	0.37	0.37	0.87	0.0	0.89	0.11	0.0	0.61	-0.21	0.45	-0.17	0.27	-0.21	0.94	0.53	0.69	0.66	0.71	0.21	-0.49	0.18
Total Stockholder Equity	0.85	0.58	0.6		0.3	-0.44	0.02	0.35	0.71	0.59	-0.29	0.71	0.11	-0.02	0.3	-0.19	0.46	0.2	0.59	0.92	0.64	0.21	0.39	0.38	-0.72	-0.09
Property Plant And Equipment Net	-0.03	-0.13	-0.23	0.3		-0.8	-0.74	-0.54	0.74	-0.42	-0.56	0.74	-0.8	0.85	-0.33	-0.01	0.55	0.8	-0.28	0.47	-0.41	-0.56	-0.47	-0.3	-0.41	-0.4
Net Debt	0.04	0.22	0.37	-0.44	-0.8		0.51	0.6	-0.91	0.41	0.44	-0.91	0.69	-0.43	0.39	0.0	-0.33	-0.59	0.39	-0.53	0.21	0.55	0.47	0.0	0.25	0.34
Retained Earnings	0.32	0.31	0.37	0.02	-0.74	0.51		0.41	-0.34	0.46	0.35	-0.33	0.63	-0.82	0.43	0.31	-0.31	-0.97	0.48	-0.04	0.46	0.62	0.51	0.33	0.22	0.48
Accounts Payable	0.72	0.78	0.87	0.35	-0.54	0.6	0.41		-0.31	0.94	0.48	-0.31	0.82	-0.43	0.54	-0.31	-0.08	-0.32	0.86	0.21	0.77	0.66	0.65	0.19	-0.22	0.17
Cash	0.33	0.11	0.0	0.71	0.74	-0.91	-0.34	-0.31		-0.08	-0.41	1.0	-0.48	0.32	-0.15	-0.1	0.43	0.48	-0.01	0.82	0.08	-0.27	-0.22	0.12	-0.44	-0.3
Non Current Assets Total	0.88	0.79	0.89	0.59	-0.42	0.41	0.46	0.94	-0.08		0.35	-0.08	0.76	-0.43	0.62	-0.24	0.03	-0.32	0.93	0.43	0.91	0.64	0.68	0.34	-0.38	0.19
Non Currrent Assets Other	0.0	0.18	0.11	-0.29	-0.56	0.44	0.35	0.48	-0.41	0.35		-0.41	0.49	-0.47	0.2	-0.25	-0.65	-0.41	0.21	-0.32	0.39	0.26	-0.13	-0.06	0.55	0.01
Cash And Short Term Investments	0.33	0.11	0.0	0.71	0.74	-0.91	-0.33	-0.31	1.0	-0.08	-0.41		-0.48	0.32	-0.15	-0.1	0.43	0.48	-0.01	0.82	0.08	-0.27	-0.22	0.12	-0.44	-0.3
Net Receivables	0.47	0.49	0.61	0.11	-0.8	0.69	0.63	0.82	-0.48	0.76	0.49	-0.48		-0.68	0.51	-0.36	-0.11	-0.6	0.65	-0.04	0.67	0.76	0.77	0.26	-0.1	0.19
Common Stock Shares Outstanding	-0.18	-0.14	-0.21	-0.02	0.85	-0.43	-0.82	-0.43	0.32	-0.43	-0.47	0.32	-0.68		-0.34	-0.13	0.57	0.82	-0.28	0.14	-0.52	-0.48	-0.4	-0.46	-0.38	-0.45
Non Current Liabilities Total	0.56	0.2	0.45	0.3	-0.33	0.39	0.43	0.54	-0.15	0.62	0.2	-0.15	0.51	-0.34		-0.17	-0.03	-0.35	0.65	0.25	0.57	0.58	0.5	0.08	-0.28	0.02
Inventory	-0.21	-0.14	-0.17	-0.19	-0.01	0.0	0.31	-0.31	-0.1	-0.24	-0.25	-0.1	-0.36	-0.13	-0.17		-0.3	-0.34	-0.19	-0.2	-0.31	-0.24	-0.21	0.12	0.39	0.67
Other Current Assets	0.35	0.28	0.27	0.46	0.55	-0.33	-0.31	-0.08	0.43	0.03	-0.65	0.43	-0.11	0.57	-0.03	-0.3		0.42	0.19	0.52	-0.07	0.18	0.41	-0.17	-0.87	-0.4
Other Stockholder Equity	-0.12	-0.16	-0.21	0.2	0.8	-0.59	-0.97	-0.32	0.48	-0.32	-0.41	0.48	-0.6	0.82	-0.35	-0.34	0.42		-0.33	0.25	-0.31	-0.56	-0.41	-0.25	-0.39	-0.5
Total Liab	0.92	0.83	0.94	0.59	-0.28	0.39	0.48	0.86	-0.01	0.93	0.21	-0.01	0.65	-0.28	0.65	-0.19	0.19	-0.33		0.54	0.79	0.68	0.69	0.27	-0.48	0.2
Total Current Assets	0.79	0.53	0.53	0.92	0.47	-0.53	-0.04	0.21	0.82	0.43	-0.32	0.82	-0.04	0.14	0.25	-0.2	0.52	0.25	0.54		0.46	0.17	0.25	0.26	-0.68	-0.13
Intangible Assets	0.81	0.61	0.69	0.64	-0.41	0.21	0.46	0.77	0.08	0.91	0.39	0.08	0.67	-0.52	0.57	-0.31	-0.07	-0.31	0.79	0.46		0.54	0.53	0.54	-0.31	0.13
Short Long Term Debt Total	0.54	0.57	0.66	0.21	-0.56	0.55	0.62	0.66	-0.27	0.64	0.26	-0.27	0.76	-0.48	0.58	-0.24	0.18	-0.56	0.68	0.17	0.54		0.79	0.21	-0.21	0.15
Short Term Debt	0.63	0.56	0.71	0.39	-0.47	0.47	0.51	0.65	-0.22	0.68	-0.13	-0.22	0.77	-0.4	0.5	-0.21	0.41	-0.41	0.69	0.25	0.53	0.79		0.27	-0.56	0.16
Common Stock	0.35	0.14	0.21	0.38	-0.3	0.0	0.33	0.19	0.12	0.34	-0.06	0.12	0.26	-0.46	0.08	0.12	-0.17	-0.25	0.27	0.26	0.54	0.21	0.27		-0.04	0.63
Current Deferred Revenue	-0.65	-0.4	-0.49	-0.72	-0.41	0.25	0.22	-0.22	-0.44	-0.38	0.55	-0.44	-0.1	-0.38	-0.28	0.39	-0.87	-0.39	-0.48	-0.68	-0.31	-0.21	-0.56	-0.04		0.34
Common Stock Total Equity	0.09	0.12	0.18	-0.09	-0.4	0.34	0.48	0.17	-0.3	0.19	0.01	-0.3	0.19	-0.45	0.02	0.67	-0.4	-0.5	0.2	-0.13	0.13	0.15	0.16	0.63	0.34

Click cells to compare fundamentals

Enveric Biosciences Account Relationship Matchups

Enveric Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	25.0M	4.1M	26.7M	19.6M	4.3M	4.1M
Other Current Liab	4.8M	681.3K	1.2M	3.4M	1.1M	1.9M
Total Current Liabilities	14.4M	681.3K	2.1M	4.0M	2.3M	3.7M
Total Stockholder Equity	10.6M	3.4M	22.3M	14.7M	2.0M	1.9M
Net Debt	4.4M	(1.6M)	(17.2M)	(17.7M)	(2.3M)	(2.2M)
Retained Earnings	(40.5M)	(11.8M)	(60.7M)	(79.2M)	(96.5M)	(91.7M)
Accounts Payable	4.7M	681.3K	683.4K	463.3K	1.2M	1.3M
Cash	431.4K	1.6M	17.4M	17.7M	2.3M	2.3M
Non Current Assets Total	17.4M	1.8M	9.0M	1.1M	718.3K	682.4K
Cash And Short Term Investments	431.4K	1.6M	17.4M	17.7M	2.3M	2.4M
Net Receivables	8.8M	7.9M	6.4M	224.6K	258.3K	245.4K
Common Stock Shares Outstanding	26.4K	115.1K	472.3K	1.4M	2.2M	2.3M
Liabilities And Stockholders Equity	25.0M	4.1M	26.7M	19.6M	4.3M	4.1M
Non Current Liabilities Total	2.4M	4.2M	9.6M	0.0	2.3M	527.1K
Other Current Assets	783.6K	1.4M	761.7K	1.3M	1.1M	1.1M
Other Stockholder Equity	51.0M	15.2M	82.7M	94.4M	99.0M	103.9M
Total Liab	14.4M	681.3K	4.4M	4.0M	2.3M	2.2M
Total Current Assets	7.6M	2.3M	17.7M	18.4M	3.6M	4.2M
Intangible Assets	3.6M	1.8M	6.9M	379.7K	210.9K	200.4K
Common Stock	25.2K	101.0K	325.8K	20.8K	27.4K	26.0K
Accumulated Other Comprehensive Income	60.0K	(181.3K)	(30.8K)	(536.7K)	(569.7K)	(598.2K)
Net Tangible Assets	(65.5K)	(1.8M)	1.6M	13.8M	15.9M	16.7M
Net Invested Capital	15.5M	3.4M	22.3M	14.7M	2.0M	1.9M
Net Working Capital	(6.8M)	1.6M	15.7M	14.4M	1.2M	909.9K
Capital Stock	29.5K	133.7K	325.8K	20.8K	27.4K	26.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:

How To Invest In Enveric

Details

Is Enveric Stock a good investment?

Details

What is Enveric Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.

You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.42)

Revenue Per Share

37.678

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.81)

Return On Equity

(2.06)

The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enveric Average Payables vs Price To Sales Ratio Analysis

Average Payables vs Price To Sales Ratio

Average Payables vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Average Payables

Price To Sales Ratio

Enveric Biosciences fundamental ratios Correlations

Enveric Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enveric Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Liabilities	+ 0.94	Other Current Liab
Total Liab	+ 0.94	Total Current Liabilities
Non Current Assets Total	+ 0.94	Accounts Payable
Total Liab	+ 0.93	Non Current Assets Total
Total Liab	+ 0.92	Total Assets

Other Stockholder Equity	- 0.97	Retained Earnings
Cash And Short Term Investments	- 0.91	Net Debt
Cash	- 0.91	Net Debt
Current Deferred Revenue	- 0.87	Other Current Assets
Common Stock Shares Outstanding	- 0.82	Retained Earnings
Net Receivables	- 0.8	Property Plant And Equipment Net